Insider Buying Cyclo Therapeutics, Inc. Director Purchases 59,881 Shares of Stock
CYTH Stock | USD 0.64 0.04 5.88% |
Under 63% of all Cyclo Therapeutics' traders are looking to take a long position. The analysis of the overall investor sentiment regarding Cyclo Therapeutics suggests that some traders are interested. Cyclo Therapeutics' investing sentiment shows overall attitude of investors towards Cyclo Therapeutics.
Cyclo |
Cyclo Therapeutics, Inc. Director Markus Sieger purchased 59,881 shares of the businesss stock in a transaction on Thursday, April 20th. The stock was acquired at an average cost of 0.71 per share, with a total value of 42,515.51. Following the completion of the acquisition, the director now directly owns 161,051 shares
Read at thelincolnianonline.com
Cyclo Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cyclo Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cyclo Therapeutics Fundamental Analysis
We analyze Cyclo Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Cyclo Therapeutics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Cyclo Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cyclo Therapeutics stock to make a market-neutral strategy. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics with similar companies.
Peers
Cyclo Therapeutics Related Equities
AMRX | Amneal Pharmaceuticals, | 3.63 | ||||
LFCR | Lifecore Biomedical | 2.97 | ||||
IRWD | Ironwood Pharmaceuticals | 2.84 | ||||
ASRT | Assertio Therapeutics | 2.00 | ||||
PAHC | Phibro Animal | 0.73 | ||||
ITCI | Intracellular | 0.44 | ||||
SSIC | Silver Spike | 0.62 | ||||
TKNO | Alpha Teknova | 1.61 | ||||
AQST | Aquestive Therapeutics | 5.50 | ||||
PTPI | Petros Pharmaceuticals | 6.90 |
Complementary Tools for Cyclo Stock analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |